Novartis Rejects Claims It Is Pushing Out Generic Competition Of Cancer Drug

Swiss drug company Novartis is fighting back against claims that it is monopolizing the Colombian market of a leukemia drug by threatening patent infringement suits against generic manufacturers. In a statement to Inside U.S. Trade , a Novartis spokeswoman said it is clear there are generics of the drug imatinib on the market. Novartis holds a patent on a modification of imatinib, called Glivec, until 2018. Non-governmental organizations in Colombia and the U.S. charged that Novartis is able to push...